PPE50 variants as novel phylogeographic signatures of host-pathogen co-evolution in tuberculosis.

Publication date: Jul 09, 2025

While evidence supports co-evolution between Mycobacterium tuberculosis and humans, underlying mechanisms remain unclear. We identified PPE50 as a novel subfamily of PE/PPE proteins comprising eight variants. Surveying 387 M. tuberculosis complex (MTBC) strains representing global phylogeography, we found PPE50 variants are lineage-specific and stably associated with geographic regions, defining them as phylogeographically-associated proteins (PAPs). PPE50-381 is the ancestral variant (present in early-branching M. canettii) and the only variant observed in both Ancient and Modern MTBC lineages. Transcriptomic analysis confirmed that ppe50 variant genes are expressed in strains from respective MTBC lineages, but not in all L1 strains and sub-lineages L2. 1 and L4. 1 where the gene was deleted. In silico analysis revealed significant structural diversity among variants, particularly in C-terminal regions. This strong association of M. tuberculosis protein diversity with phylogeography suggests PPE50 may contribute to MTBC adaptation to different host populations. Further characterization of PPE50 and other PAPs may facilitate improved targeted diagnostics, therapeutics and vaccines.

Open Access PDF

Concepts Keywords
387m Antigens, Bacterial
Modern Antigens, Bacterial
Mycobacterium Bacterial Proteins
Phylogeography Bacterial Proteins
Tuberculosis Evolution, Molecular
Genetic Variation
Host-Pathogen Interactions
Humans
Mycobacterium tuberculosis
Phylogeny
Phylogeography
Tuberculosis

Semantics

Type Source Name
disease IDO host
disease IDO pathogen
disease MESH tuberculosis
pathway KEGG Tuberculosis
disease IDO protein
disease MESH infectious diseases
disease IDO bacteria
drug DRUGBANK Glutamic Acid
disease MESH infection
disease IDO cell
disease MESH latent infection
disease MESH histocompatibility
disease IDO production
disease IDO blood
drug DRUGBANK Meticillin
disease IDO virulence
drug DRUGBANK Coenzyme M
drug DRUGBANK Amino acids
drug DRUGBANK Serine
drug DRUGBANK L-Valine
drug DRUGBANK Proline
drug DRUGBANK Methylergometrine
drug DRUGBANK Abacavir
drug DRUGBANK Flunarizine
drug DRUGBANK Acetaminophen
disease IDO history
disease IDO site
disease MESH oxidative stress
disease MESH hypoxia
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
drug DRUGBANK BCG vaccine
pathway KEGG Homologous recombination
drug DRUGBANK Ademetionine
drug DRUGBANK N-Cyclohexyltaurine
drug DRUGBANK Steviolbioside
drug DRUGBANK Nonoxynol-9
drug DRUGBANK N-acetylsulfanilyl chloride
disease IDO homo sapiens
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Nitric Oxide
disease MESH drug tolerance
disease MESH cancer
pathway REACTOME Immune System
disease MESH Comas
disease MESH granuloma
disease IDO susceptibility
drug DRUGBANK Acetylsalicylic acid
disease MESH mixed infections
disease IDO quality
disease IDO algorithm
drug DRUGBANK Metolazone
pathway REACTOME Reproduction

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *